Similar results were observed when isatuximab was given in combination with cemiplimab (anti-PD-1) in patients with advanced NSCLC and metastatic castration-resistant prostate cancer,18 suggesting no effect of PD-1/PD-L1 blockade on isatuximab PK. This evidence concerns the gene CD274 and non-small cell lung carcinoma.